Private Genome Sequencing Effort May Hasten Separate Public Venture

Leaders of separate public and private efforts to sequence the human genome used words such as "cooperation," "collaboration," and "partnership" to describe their intentions toward each other during a hearing last month in Washington, D.C. But both projects appear headed on separate, although not quite independent, courses. The private project--a joint venture between Perkin-Elmer Inc., a Norwalk, Conn.-based manufacturer of sequencing equipment, and J. Craig Venter, president of The Institute

Written byPaul Smaglik
| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

Leaders of separate public and private efforts to sequence the human genome used words such as "cooperation," "collaboration," and "partnership" to describe their intentions toward each other during a hearing last month in Washington, D.C. But both projects appear headed on separate, although not quite independent, courses.

The private project--a joint venture between Perkin-Elmer Inc., a Norwalk, Conn.-based manufacturer of sequencing equipment, and J. Craig Venter, president of The Institute for Genomic Research (TIGR) in Rockville, Md.--seeks to complete its version of the human genome by the year 2001. The yet-to-be-named company will use highly automated sequencing machines that Perkin-Elmer recently unveiled, greater computational power, and the "whole genome shotgun" sequencing strategy to blast 10 human genomes into billions of base pairs, then reassemble them, in order.

The federally sponsored Human Genome Project, will continue to plug away using a clone-by-clone approach to slowly build billions of DNA pieces into ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies